Close Menu

financial results

The firm said that immunoassays had 19 years in a row of double-digit growth, driven in part by an automated workflow approach to achieving lab efficiencies. 

The firm's life science segment grew revenues 8 percent, but revenues from its diagnostics segment saw revenues retreated 4 percent. 

The company plans to expand into new markets through its recent acquisition of Alere Triage assets.

The growth was driven in part by a strong increase in revenues for the company's life sciences research products.

Total revenues reached $2.54 billion during the quarter, while LabCorp Diagnostics' revenues rose more than 8 percent to $1.80 billion. 

The company, which beat analyst estimates on both the top and bottom lines, said completed Cologuard test volume rose 149 percent to 135,000 tests.

NeoGenomics' clinical genetic testing revenues were up 7 percent year over year, as the number of genetic tests completed increased by 16 percent.

On a conference call, the firm's CEO said that it and other industry players are pushing to postpone implementation of PAMA to no earlier than July 1, 2018. 

BioMérieux's organic growth saw a 9 percent increase to €566.4 million from €512.3 million in Q2 2016.

Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round. 

Pages